{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:01:29Z","timestamp":1791820889867,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009129","name":"Evidence Synthesis Programme","doi-asserted-by":"publisher","award":["NIHR16121"],"award-info":[{"award-number":["NIHR16121"]}],"id":[{"id":"10.13039\/501100009129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10198-025-01868-2","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:40:10Z","timestamp":1763458810000},"page":"945-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS"],"prefix":"10.1007","volume":"27","author":[{"given":"Matthew","family":"Walton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyanar Jasmine","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyereugo","family":"Umemneku-Chikere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Yew","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":false,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ODRR.S69109","volume":"7","author":"JF Cabello","year":"2017","unstructured":"Cabello, J.F., Marsden, D.: Pompe disease: Clinical perspectives. Orphan Drugs Res Rev 7, 1\u201310 (2017)","journal-title":"Orphan Drugs Res Rev"},{"key":"1868_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"JA Lim","year":"2014","unstructured":"Lim, J.A., Li, L., Raben, N.: Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 6, 177 (2014)","journal-title":"Front Aging Neurosci"},{"key":"1868_CR3","unstructured":"National Institutes of Health.: Pompe disease. Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/pompe-disease (n.d.). Accessed 13 Dec 2023"},{"issue":"1\u20132","key":"1868_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg, A., Carlier, P.G., Carlier, R.Y., Kissel, J.T., Schoser, B., Wenninger, S., et al.: Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study. Mol. Genet. Metab. 119(1\u20132), 115\u2013123 (2016)","journal-title":"Mol. Genet. Metab."},{"issue":"15","key":"1868_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A.T., Clemens, P.R., Corzo, D., Escolar, D.M., Florence, J., Groeneveld, G.J., et al.: A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N. Engl. J. Med. 362(15), 1396\u20131406 (2010)","journal-title":"N. Engl. J. Med."},{"issue":"9646","key":"1868_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg, A.T., Reuser, A.J.: Pompe\u2019s disease. Lancet 372(9646), 1342\u20131353 (2008)","journal-title":"Lancet"},{"issue":"6","key":"1868_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A.T., Kruijshaar, M.E., Toscano, A., Lafor\u00eat, P., Angelini, C., Lachmann, R.H., et al.: European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur. J. Neurol. 24(6), 768 (2017)","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"1868_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r, D., Kruijshaar, M.E., Plug, I., Rizopoulos, D., Kanters, T.A., Wens, S.C.A., et al.: Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J. Inherit. Metab. Dis. 39(2), 253\u2013260 (2016)","journal-title":"J. Inherit. Metab. Dis."},{"key":"1868_CR9","unstructured":"National Specialised Commissioning Advisory Group.: Lysosomal storage disorders: Policy on the funding of enzyme replacement therapy and substrate reduction therapy. Available from: https:\/\/web.archive.org\/web\/20090409234844\/http:\/\/www.ncg.nhs.uk\/documents\/lsd_nscag_policy_on_funding_of_ert_and_lsd-280307.pdf (2008). Accessed 1 March 2024"},{"key":"1868_CR10","unstructured":"Department of Health.: National specialist commissioning advisory group: Annual report 2006\/7. Available from: https:\/\/web.archive.org\/web\/20090409234907\/http:\/\/www.ncg.nhs.uk\/documents\/ar_nscag_annual_report_2006-07.pdf (2007). Accessed 1 March 2024"},{"key":"1868_CR11","unstructured":"Department of Health.: National designation and funding of the service for patients with lysosomal storage disorders. Available from: https:\/\/web.archive.org\/web\/20090409235113\/http:\/\/www.ncg.nhs.uk\/documents\/lsd_letter_national_designation_and_funding_of_the_lsd_service-281004.pdf (2004). Accessed 1 March 2024"},{"key":"1868_CR12","unstructured":"Deegan P.: Guidelines for the investigation and management of late onset acid maltase deficiency (type ii glycogen storage disease \/ Pompe disease). Available from: https:\/\/web.archive.org\/web\/20090409234808\/http:\/\/www.ncg.nhs.uk\/documents\/lsd_guidelines_for_adult_pompe_disease_000308.pdf (2007). Accessed 1 March 2024"},{"issue":"3","key":"1868_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5582\/irdr.2020.03028","volume":"9","author":"R Hashempour","year":"2020","unstructured":"Hashempour, R., Davari, M., Pourreza, A., Alaei, M., Ahmadi, B.: Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market. Irdr 9(3), 130\u2013136 (2020)","journal-title":"Irdr"},{"issue":"1","key":"1868_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-017-0731-0","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters, T.A., van der Ploeg, A.T., Kruijshaar, M.E., Rizopoulos, D., Redekop, W.K., Rutten-van Molken, M., Hakkaart-van, R.L.: Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis 12(1), 179 (2017)","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1868_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-9-75","volume":"16","author":"TA Kanters","year":"2014","unstructured":"Kanters, T.A., Hoogenboom-Plug, I., Rutten-Van Molken, M.P., Redekop, W.K., van der Ploeg, A.T., Hakkaart, L.: Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet J. Rare Dis. 16(9), 75 (2014)","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"1868_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S0124-00642012000100012","volume":"14","author":"HE Castro-Jaramillo","year":"2012","unstructured":"Castro-Jaramillo, H.E.: The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country\u2019s approach (England) to that of a middle-income one (Colombia). Revista de Salud Publica 14(1), 143\u201355 (2012)","journal-title":"Revista de Salud Publica"},{"key":"1868_CR17","unstructured":"National Institute for Health and Care Excellence.: Avalglucosidase alfa for treating Pompe disease [TA821]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta821 (2022). Accessed Dec 2023"},{"key":"1868_CR18","unstructured":"National Institute for Health and Care Excellence.: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease [TA912]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta912 (2023). Accessed Dec 2023"},{"key":"1868_CR19","unstructured":"National Institute for H, Care E.: Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821. England: National Institute for Health and Care Excellence (NICE) (2022)"},{"key":"1868_CR20","unstructured":"National Institute for H, Care E.: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912. England: National Institute for Health and Care Excellence (NICE) (2023)"},{"issue":"1","key":"1868_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-025-03981-0","volume":"20","author":"M Corbett","year":"2025","unstructured":"Corbett, M., Umemneku-Chikere, C., Nevitt, S., Deng, N.J., Walton, M., Fulbright, H., et al.: Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: A systematic review and network meta-analysis. Orphanet J. Rare Dis. 20(1), 14 (2025)","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"1868_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","volume":"15","author":"J Karnon","year":"2012","unstructured":"Karnon, J., Stahl, J., Brennan, A., Caro, J.J., Mar, J., M\u00f6ller, J.: Modeling using discrete event simulation: A report of the ISPOR-SMDM modeling good research practices task force-4. Value Health 15(6), 821\u20137 (2012)","journal-title":"Value Health"},{"issue":"2","key":"1868_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.36469\/jheor.2024.121928","volume":"11","author":"A MacCulloch","year":"2024","unstructured":"MacCulloch, A., Griffiths, A., Johnson, N., Shohet, S.: Health-related quality-of-life utility values in adults with late-onset Pompe disease: analyses of EQ-5D data from the PROPEL clinical trial. J. Health Econ. Outcomes Res. 11(2), 80\u201385 (2024)","journal-title":"J. Health Econ. Outcomes Res."},{"key":"1868_CR24","unstructured":"Davis, S., Stevenson, M., Tappenden, P., Wailoo, A.: NICE DSU technical support document 15: cost-effectiveness modelling using patient-level simulation. London: National Institute for Health and Care Excellence (NICE) (2014)"},{"issue":"6","key":"1868_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","volume":"80","author":"PS Kishnani","year":"2023","unstructured":"Kishnani, P.S., Diaz-Manera, J., Toscano, A., Clemens, P.R., Ladha, S., Berger, K.I., et al.: Efficacy and safety of avalglucosidase alfa in patients with late-onset pompe disease after 97 weeks: A phase 3 randomized clinical trial. JAMA Neurology 80(6), 558\u201367 (2023)","journal-title":"JAMA Neurology"},{"issue":"Supplement 1","key":"1868_CR26","first-page":"A30","volume":"4","author":"R Henderson","year":"2022","unstructured":"Henderson, R., Kishnani, P.S., Diaz-Manera, J., Kushlaf, H., Ladha, S., Mozaffar, T., et al.: Efficacy and safety of Avalglucosidase Alfa in participants with late-onset pompe disease after 97 weeks of treatment during the comet trial. BMJ Neurology Open. 4(Supplement 1), A30\u2013A31 (2022)","journal-title":"BMJ Neurology Open."},{"issue":"6","key":"1868_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini, C., De Antonio, M., Taouagh, N., Behin, A., Bouhour, F., Echaniz-Laguna, A., et al.: Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. J Inherit Metab Dis 43(6), 1219\u201331 (2020)","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1868_CR28","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","volume":"158","author":"PL Enright","year":"1998","unstructured":"Enright, P.L., Sherrill, D.L.: Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 158(5), 1384\u20131387 (1998)","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"1868_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-018-0824-4","volume":"13","author":"JC van der Meijden","year":"2018","unstructured":"van der Meijden, J.C., Kruijshaar, M.E., Rizopoulos, D., van Doorn, P.A., van der Beek, N., van der Ploeg, A.T.: Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients. Orphanet J Rare Dis. 13(1), 82 (2018)","journal-title":"Orphanet J Rare Dis."},{"issue":"19","key":"1868_CR30","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar, L., Hogrel, J.Y., Perniconi, B., Kruijshaar, M.E., Rizopoulos, D., Taouagh, N., et al.: Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93(19), e1756\u2013e67 (2019)","journal-title":"Neurology"},{"issue":"3","key":"1868_CR31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg, A.T., Barohn, R., Carlson, L., Charrow, J., Clemens, P.R., Hopkin, R.J., et al.: Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol. Genet. Metab. 107(3), 456\u2013461 (2012)","journal-title":"Mol. Genet. Metab."},{"issue":"15","key":"1868_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A.T., Clemens, P.R., Corzo, D., Escolar, D.M., Florence, J., Groeneveld, G.J., et al.: A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N. Engl. J. Med. 362(15), 1396\u20131406 (2010)","journal-title":"N. Engl. J. Med."},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","volume":"271","author":"B Schoser","year":"2024","unstructured":"Schoser, B., Kishnani, P.S., Bratkovic, D., Byrne, B.J., Claeys, K.G., Diaz-Manera, J., et al.: 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). J. Neurol. 271, 2810\u20132823 (2024)","journal-title":"J. Neurol."},{"issue":"1","key":"1868_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","volume":"30","author":"HA van Kooten","year":"2020","unstructured":"van Kooten, H.A., Harlaar, L., van der Beek, N., van Doorn, P.A., van der Ploeg, A.T., Brusse, E.: Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria. Neuromuscul Disord 30(1), 59\u201366 (2020)","journal-title":"Neuromuscul Disord"},{"key":"1868_CR35","unstructured":"Office for National Statistics.: National life tables - life expectancy in the UK: 2021 to 2023 (2024)"},{"issue":"8","key":"1868_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"27","author":"D Gungor","year":"2013","unstructured":"Gungor, D., Kruijshaar, M.E., Plug, I., D\u2019Agostino, R.B., Hagemans, M.L., van Doorn, P.A., et al.: Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J. Rare Dis. 27(8), 49 (2013)","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"1868_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara, R., Brazier, J.E.: Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 14(4), 539\u2013545 (2011)","journal-title":"Value Health"},{"issue":"1","key":"1868_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.36469\/jheor.2023.68157","volume":"10","author":"L Hubig","year":"2023","unstructured":"Hubig, L., Sussex, A.K., MacCulloch, A., Hughes, D., Graham, R., Morris, L., et al.: Quality of life with late-onset Pompe disease: Qualitative interviews and general public utility estimation in the United Kingdom. Journal of Health Economics and Outcomes Research 10(1), 41\u201350 (2023)","journal-title":"Journal of Health Economics and Outcomes Research"},{"key":"1868_CR39","unstructured":"Joint Formulary Committee.: British national formulary. BMJ Publishing and the Royal Pharmaceutical Society (2025)"},{"key":"1868_CR40","unstructured":"European Medicines Agency.: Opfolda (miglustat): Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opfolda-epar-product-information_en.pdf (2025). Accessed Sept 2025"},{"key":"1868_CR41","unstructured":"European Medicines Agency.: Pombiliti (cipaglucosidase alfa): Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pombiliti-epar-product-information_en.pdf (2024). Accessed Sept 2025"},{"key":"1868_CR42","unstructured":"European Medicines Agency.: Nexviadyme (avalglucosidase alfa): Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexviadyme-epar-product-information_en.pdf (2024). Accessed Sept 2025"},{"key":"1868_CR43","unstructured":"European Medicines Agency.: Myozyme (alglucosidase alfa): Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myozyme-epar-product-information_en.pdf (2024). Accessed Sept 2025"},{"key":"1868_CR44","unstructured":"National Health Service.: 2023\/24 National cost collection data publication. Available from: https:\/\/www.england.nhs.uk\/publication\/2023-24-national-cost-collection-data-publication\/ (2024). Accessed 20 Jan 2025"},{"key":"1868_CR45","unstructured":"Jones, K.C., Weatherley, H., Birch, S., Castelli, A., Chalkley, M., Dargan, A. et al.: Unit costs of health and social care 2023 manual: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York) (2024)"},{"issue":"11","key":"1868_CR46","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli, N.C., Rutten-van M\u00f6lken, M., Severens, J.L., Al, M.: TECH-VER: A verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics 37(11), 1391\u20131408 (2019)","journal-title":"Pharmacoeconomics"},{"key":"1868_CR47","unstructured":"Inc A.: AAV2\/\u200b8-LSPhGAA (ACTUS-101) in late-onset pompe disease. ClinicalTrials.gov Identifier: NCT03533673. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03533673 (n.d.). Accessed 27 Jan 2025"},{"key":"1868_CR48","unstructured":"Florida Uo.: Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease (AAV9-GAA_IM) ClinicalTrials.gov Identifier: NCT02240407. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02240407 (n.d.). Accessed 27 Jan 2025"},{"key":"1868_CR49","unstructured":"Spark Therapeutics I.: A gene transfer study for late-onset pompe disease (RESOLUTE). ClinicalTrials.gov Identifier: NCT02240407. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04093349 [ (n.d.). Accessed 27 Jan 2025]"},{"key":"1868_CR50","unstructured":"Inc G.: Evaluation of the safety and efficacy of late-onset pompe disease gene therapy drug. ClinicalTrials.gov Identifier: NCT06391736. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06391736 (n.d.). Accessed 27 Jan 2025"},{"key":"1868_CR51","unstructured":"Hospital H.: Evaluation of the safety, tolerability and efficacy of gene therapy drug for late onset pompe disease (LOPD). ClinicalTrials.gov Identifier: NCT06178432. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06178432 (n.d.). Accessed 27 Jan 2025]"},{"key":"1868_CR52","unstructured":"Inc AP.: Gene Transfer study in patients with late onset pompe disease (FORTIS). ClinicalTrials.gov Identifier: NCT04174105. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04174105 (n.d.). Accessed 27 Jan 2025"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01868-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:55:01Z","timestamp":1786085701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01868-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01868-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to update the funding note in the article with \"The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}